Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Pediatric acute myeloid leukemias are serious diseases with a poor outlook and a high chance of relapse. This research aims to collect biological samples to study the genetic makeup of leukemic cells from children, teenagers, and young adults at diagnosis or relapse. The goal is to better understand the key genetic changes that cause resistance and may predict relapse risk. The study also explores bone marrow stem cells and tests how leukemic cells respond to multiple drugs outside the body. Participants include those under 25 years old with acute myeloid leukemia at first diagnosis or relapse, as well as patients with a genetic risk for leukemia or those undergoing bone marrow sampling without leukemia to serve as controls. Blood and bone marrow samples are collected, with multiple tubes taken at diagnosis and relapse for those with leukemia, and single samples for others. These samples are used for genetic sequencing, expression profiling, and drug testing. During the study, researchers will analyze the number of genetic mutations and other molecular features up to five years after sample collection. They will monitor relapse rates, survival without events, and disease-free survival. Other measurements include stem cell profiles, drug response patterns, and clearance of minimal residual disease. Participants may be followed for up to five years to assess these outcomes and better understand leukemia biology and treatment resistance.
Actively Recruiting
Researchers are conducting a Phase III international trial to study the effects and safety of androgen deprivation therapy ADT with or without darolutamide in men newly diagnosed with metastatic prostate cancer who have vulnerable functional abilities. This study specifically includes patients who have not chosen treatment with docetaxel or other androgen receptor pathway inhibitors. The goal is to evaluate how these treatments impact disease progression and patient health over time. Participants will be randomly assigned to one of two groups one receiving ADT plus darolutamide 600 mg taken orally twice daily, and the other receiving ADT plus a placebo taken with the same schedule. Treatment will continue until imaging shows disease progression or until the patient or doctor decides to stop for reasons such as side effects or other health issues. After stopping treatment, patients will enter a follow-up phase lasting up to 10 years to monitor survival, further treatments, and any ongoing or new side effects. During the study, participants will undergo regular assessments including imaging scans to check for cancer progression, blood tests, evaluations of urinary symptoms, and quality of life questionnaires. Researchers will track outcomes like progression-free survival, overall survival, symptom changes, and adverse events. Monitoring visits will occur periodically both during treatment and follow-up to gather comprehensive data on health status and treatment effects.
Actively Recruiting
This research aims to reduce extubation failure in critically ill patients with acute brain injuries who have impaired consciousness. These patients often require mechanical ventilation with tracheal intubation, and after their acute neurological condition is treated, doctors need to carefully wean them off ventilators to avoid complications like pneumonia. Current guidelines for ventilator weaning do not include brain-injured patients with impaired consciousness, so this study evaluates a simple clinical score to help decide when to safely remove the breathing tube. Participants will be assigned by random clusters of intensive care units to receive either usual care or care guided by the extubation readiness clinical score. After a successful spontaneous breathing trial, clinicians in the intervention group will use the score based on swallowing, gag reflex, cough, and consciousness level to decide on extubation. If the score is above 9, extubation should proceed. Those in the usual care group will follow standard ICU ventilator weaning protocols. The study uses a stepped wedge cluster randomized design. During the study, patients are assessed daily for readiness to breathe without the ventilator. Researchers will monitor extubation failure from the time of extubation up to five days later. They will also track other outcomes such as time to extubation, duration of mechanical ventilation, reintubation rates, pneumonia occurrence, hospital stay length, and neurological outcomes up to 90 days. This thorough evaluation helps understand how the score may improve the timing and success of extubation in this vulnerable group.
Actively Recruiting
Researchers are studying moderate facial acne in patients with darker skin tones, specifically Fitzpatrick skin types IV to VI. The study aims to compare the effects of oral isotretinoin as a first-line treatment versus the current standard care, which includes oral antibiotics and topical creams, focusing on the severity of acne-related pigmentation after six months. Acne affects about 9% of the global population and can impact quality of life, especially in people of color who often experience pigmentation issues linked to acne. Participants will be assigned to one of two groups. One group receives oral isotretinoin starting at 0.5 mgkgday, with possible dose adjustments based on tolerance and effectiveness over six months. The other group receives standard care, consisting of topical tretinoin or adapalene cream daily combined with doxycycline or lymecycline 100 mgday for three months, followed by assessment and possible continuation of topical treatment only. Participants in the isotretinoin group are followed monthly, while those in the standard care group have visits at 3 and 6 months. During the study, participants will be monitored for acne-related pigmentation severity, quality of life, and adverse events over six months. Assessments include clinical evaluations and self-photography using a smartphone with adequate camera resolution. Safety monitoring involves checking blood tests and pregnancy status for women of childbearing potential. The trial is randomized, open-label, and aims to enroll 420 participants aged 13 to 30 years with moderate acne and skin types IV to VI.
Actively Recruiting
Vitiligo affects about 1 to 2% of people worldwide and can greatly reduce quality of life. Researchers are studying how the drug ritlecitinib, which blocks certain enzymes involved in the immune response, works alone or combined with narrowband UVB light therapy to treat vitiligo. This study aims to compare the improvement in vitiligo severity on the face and body after 52 weeks between these two treatment approaches. Participants will be randomly assigned to receive either ritlecitinib 100 mg once daily by mouth alone or combined with narrowband UVB light therapy twice weekly for 52 weeks. After this period, all participants will continue taking ritlecitinib 100 mg daily in an open-label phase. The study will include patients with different skin types and vitiligo that is either active or stable. Treatment effects will be evaluated across these groups. Participants will attend eight study visits over about 72 weeks for assessments including skin evaluations, blood sample collection, and pregnancy tests every four weeks for women who can become pregnant. Some volunteers will have skin biopsies at baseline, week 4, and week 52. Researchers will measure changes in vitiligo severity using scoring indexes focused on the face and total body. Safety and quality of life will also be monitored throughout the study.
Actively Recruiting
Researchers are studying congenital nevus CN, a pigmented skin lesion present at birth that grows with the child. CN varies in size from small to giant and is linked to genetic mutations in the NRASBRAF genes. Large CNs may increase risks of neurological disorders like neuro-meningeal melanosis and brain malformations, early developmental delays, and melanoma, though smaller CNs carry a lower cancer risk. The study also considers the psychological impact on families and the childs social life. The study involves children under 2 years old with medium to giant CN according to the Krengel classification. Participants undergo neurodevelopmental assessments using the ASQ-3 test, meetings with parents to evaluate lesion acceptance and quality of life via the MARKS test, and collection of patient quality of life data. The study aims to clarify monitoring and treatment guidelines, including the need for brain imaging and surgical intervention criteria. Participants are followed for 3 years with evaluations of neurodevelopmental abnormalities, neurological conditions, early melanoma occurrence, and changes in CN characteristics. Researchers also review histopathological and molecular data if biopsies or excisions occur. Parental satisfaction and patient well-being are assessed using questionnaires like the Cartoon CDLQI test. The main outcome is the prevalence of neurodevelopmental abnormalities at age 3, helping to improve care and quality of life for children with CN.
Actively Recruiting
Researchers are studying how inhaled aromatherapy using a mixture of ginger and lemon essential oils can help manage nausea and vomiting caused by chemotherapy in patients with blood cancers. This study aims to see if adding this aromatherapy to standard anti-nausea treatments improves nausea scores, quality of life, and appetite during the first day of chemotherapy treatment. The trial is conducted across multiple centers with experienced medical and nursing staff coordinating the safe and scientific use of aromatherapy. Participants are randomly assigned to one of two groups one receives the usual anti-nausea treatment plus inhalation of the ginger and lemon essential oil blend, while the other receives the same standard care plus a placebo aromastick with a neutral, odorless oil. Patients will use their assigned aromastick during three chemotherapy cycles. The study uses a double-blind design to compare the effects of the inhaled aromatherapy against placebo. During the study, participants will be monitored for nausea and vomiting intensity at various times up to three months after treatment begins. Researchers will also assess quality of life, dietary intake, and the use of antiemetic medications. The study includes evaluations at one day, four days, one month, two months, and three months to gather comprehensive data on symptoms and overall well-being. The total participation period covers multiple chemotherapy cycles and follow-up assessments to understand the impact of aromatherapy on chemotherapy-induced nausea and vomiting.
Actively Recruiting
Researchers are conducting a multicenter, phase 3, open-label study to evaluate treatments for patients with newly diagnosed Multiple Myeloma who are eligible for autologous stem cell transplantation ASCT. The study compares the effects of an experimental combination of elranatamab and lenalidomide against the current standard of care, including chemotherapy, ASCT, and maintenance therapies. The purpose is to assess if these new treatment approaches improve outcomes such as minimal residual disease MRD negativity and progression-free survival. Participants will first undergo induction therapy with four cycles of D-VRd daratumumab, bortezomib, lenalidomide, dexamethasone. Then, they will be randomly assigned to one of two consolidation therapies either standard treatment with high-dose chemotherapy and ASCT followed by D-VRd consolidation, or an experimental consolidation with elranatamab and lenalidomide. After consolidation, patients are re-randomized into maintenance therapy groups receiving either daratumumab plus lenalidomide or elranatamab monotherapy for approximately two years, with treatment adjustments based on MRD status. Throughout the study, participants will have scheduled visits for treatment administration, monitoring, and various assessments including blood tests, imaging, and quality of life questionnaires. Researchers will measure key outcomes such as MRD negativity rates, progression-free survival, overall survival, safety, and tolerability over several years. The study also tracks health-related quality of life and adverse events during induction, consolidation, and maintenance phases, with follow-up extending up to 11 years.
Actively Recruiting
This observational study focuses on adults aged 18 years and older diagnosed with Philadelphia chromosome positive Ph or BCRABL1 acute lymphoblastic leukemia ALL. It aims to collect real-world data on patients treated with a combination of BCRABL1 inhibitors alongside chemotherapy, corticosteroids, or monoclonal antibodies. The study is sponsored by Versailles Hospital and seeks to better understand treatment outcomes in this specific patient group. Participants have already received or are receiving treatment that combines BCRABL1 inhibitors with other therapies such as chemotherapy, corticosteroids, or monoclonal antibodies. This study observes these treatments without assigning any new interventions, focusing on the natural course and outcomes of this combined treatment approach in routine clinical care. Throughout the study, participants health and treatment responses are monitored over several years. Researchers will evaluate overall survival at 12 and 36 months, remission rates, molecular responses in bone marrow and blood, event-free and relapse-free survival, mutation incidence, treatment tolerance, and deaths during induction and remission. Data collection will involve regular assessments aligned with standard medical care, and participation may last until study completion in late 2027.
Actively Recruiting
Researchers are evaluating new treatment strategies for children and adults with newly diagnosed and relapsed rhabdomyosarcoma RMS in a multi-arm, multi-stage clinical trial called FaR-RMS. The study aims to assess the impact of new drug regimens, the effects of changing maintenance therapy duration, the influence of radiotherapy dose and timing, and the use of genetic and imaging markers to improve risk stratification and predict outcomes. Participants may receive various chemotherapy drugs including irinotecan, ifosfamide, vincristine, actinomycin, doxorubicin, vinorelbine, cyclophosphamide, temozolomide, and regorafenib administered through infusions or oral tablets on specific schedules. Radiotherapy is also given in different doses and timings depending on the treatment arm. The study includes dose-finding phases and multiple randomizations based on patient risk group and disease status. Throughout the study, participants undergo regular assessments including monitoring for event-free survival, local failure-free survival, toxicity, response to treatment, and quality of life using questionnaires. Follow-up may continue for several years to track progression and survival. Safety is closely monitored with evaluations of acute and late complications, and treatment tolerability is assessed. The study involves written consent and requires participants to use contraception if applicable during and after treatment.
1-10 of 18
1